Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

We employed a customized multiple myeloma (mm)-specific mutation panel (m3p) to screen a homogenous cohort of 142 untreated mm patients for relevant mutations in a selection of disease-specific genes. m3pv2.0 includes 77 genes selected for being either actionable targets,potentially related to drug-response or part of known key pathways in mm biology. we identified mutations in potentially actionable genes in 49% of patients and provided prognostic evidence of stat3 mutations. this panel may serve as a practical alternative to more comprehensive sequencing approaches,providing genomic information in a timely and cost-effective manner,thus allowing clinically oriented variant screening in mm.